Javascript must be enabled to continue!
Analysis of LpA levels in young patients after ACS: getting to know less famous risk factors
View through CrossRef
Abstract
Introduction
Lipoprotein A (LpA) has been shown to be an emerging risk factor, proposing that values greater than 60 mg/dl increases cardiovascular risk. There are few data about LpA values in young patients who have suffered a major cardiovascular event.
Purpose
The objective of this work was to describe the LpA values observed in young patients admitted for acute coronary syndrome in our center, and subsequently to compare these values according to the patients' previous cardiovascular risk.
Methods
This is a descriptive and observational study, in which all male patients under 65 years and women under 70 years who have suffered STEMI or NSTEMI from November 2019 to February 2021 admitted to our center were consecutively included. In addition to LpA values, the following variables were recollected: age, sex, high blood pressure, diabetes mellitus, dyslipidemia, stroke, chronic kidney injury, smoking, alcoholism, toxics, total cholesterol and SCORE risk.
Results
159 patients were included. The mean of LpA value was 41,08 mg/dl (standard deviation 38, range 1–155, percentile 25th: 9,7; percentile 50th: 28,8; percentile 75th: 59,1). 24,5% presented levels of LpA greater than 60 mg/dl. The percentage of patients with LpA levels >60 mg was 32,4% in low SCORE group and 22,4% in greater than low SCORE group without significant differences.
The table compares the LpA values according to the cardiovascular risk SCORE those patients presented before the acute coronary syndrome (low SCORE vs moderate, high or very high SCORE). As we can see in the table, we found a trend to present higher LpA values in patients with low SCORE risk compared to those with higher than low SCORE risk, without reaching statistical significance.
Conclusions
In a sample of young patients with acute coronary syndrome, the LpA mean was 41,08 mg/dl. 24,5% of patients had values of LpA greater than 60 mg/dl. No significant differences were found according to the SCORE prior to the event, although there was a non-significant trend towards a higher LpA in patients with low SCORE.
Funding Acknowledgement
Type of funding sources: None. Table 1. LpA values
Oxford University Press (OUP)
Title: Analysis of LpA levels in young patients after ACS: getting to know less famous risk factors
Description:
Abstract
Introduction
Lipoprotein A (LpA) has been shown to be an emerging risk factor, proposing that values greater than 60 mg/dl increases cardiovascular risk.
There are few data about LpA values in young patients who have suffered a major cardiovascular event.
Purpose
The objective of this work was to describe the LpA values observed in young patients admitted for acute coronary syndrome in our center, and subsequently to compare these values according to the patients' previous cardiovascular risk.
Methods
This is a descriptive and observational study, in which all male patients under 65 years and women under 70 years who have suffered STEMI or NSTEMI from November 2019 to February 2021 admitted to our center were consecutively included.
In addition to LpA values, the following variables were recollected: age, sex, high blood pressure, diabetes mellitus, dyslipidemia, stroke, chronic kidney injury, smoking, alcoholism, toxics, total cholesterol and SCORE risk.
Results
159 patients were included.
The mean of LpA value was 41,08 mg/dl (standard deviation 38, range 1–155, percentile 25th: 9,7; percentile 50th: 28,8; percentile 75th: 59,1).
24,5% presented levels of LpA greater than 60 mg/dl.
The percentage of patients with LpA levels >60 mg was 32,4% in low SCORE group and 22,4% in greater than low SCORE group without significant differences.
The table compares the LpA values according to the cardiovascular risk SCORE those patients presented before the acute coronary syndrome (low SCORE vs moderate, high or very high SCORE).
As we can see in the table, we found a trend to present higher LpA values in patients with low SCORE risk compared to those with higher than low SCORE risk, without reaching statistical significance.
Conclusions
In a sample of young patients with acute coronary syndrome, the LpA mean was 41,08 mg/dl.
24,5% of patients had values of LpA greater than 60 mg/dl.
No significant differences were found according to the SCORE prior to the event, although there was a non-significant trend towards a higher LpA in patients with low SCORE.
Funding Acknowledgement
Type of funding sources: None.
Table 1.
LpA values.
Related Results
ASSOCIATION OF THE SERUM LEVELS OF C-REACTIVE PROTEIN WITH ITS GENE POLYMORPHISMS AND ACUTE CORONARY SYNDROME
ASSOCIATION OF THE SERUM LEVELS OF C-REACTIVE PROTEIN WITH ITS GENE POLYMORPHISMS AND ACUTE CORONARY SYNDROME
Objectives
To investigate the association of the serum levels of CRP with its gene polymorphisms and the risk of ACS in Chinese Han population in Sunan region.
...
Distribution of sialoglycoconjugates on acinar cells of the mammalian pancreas.
Distribution of sialoglycoconjugates on acinar cells of the mammalian pancreas.
Using the sialic acid-specific lectin, limulin (LPA; from Limulus polyphemus hemolymph), the distribution and nature of sialoglycoconjugates on the surface of rat pancreatic cells ...
Lysophosphatidic Acid-induced EGFR Transactivation Promotes Gastric Cancer DNA Replication Through Up-Regulation of Geminin
Lysophosphatidic Acid-induced EGFR Transactivation Promotes Gastric Cancer DNA Replication Through Up-Regulation of Geminin
Abstract
BackgroundLysophosphatidic acid (LPA) is one of the simplest active phospholipid molecules. Binding to its receptors on the cell surface, LPA initiates various int...
Tissue-Engineered “Metastases”: Treatment of Hepatic Colon Tumors with a Dual Action Autotaxin Inhibitor-Lysophosphatidic Acid Receptor Antagonist
Tissue-Engineered “Metastases”: Treatment of Hepatic Colon Tumors with a Dual Action Autotaxin Inhibitor-Lysophosphatidic Acid Receptor Antagonist
Lysophosphatidic acid (LPA) acts via G protein coupled receptors (GPCRs) to regulate critical cellular functions and pathophysiological levels of LPA or its receptors are linked to...
LPA2 (EDG4) mediates Rho-dependent chemotaxis with lower efficacy than LPA1 (EDG2) in breast carcinoma cells
LPA2 (EDG4) mediates Rho-dependent chemotaxis with lower efficacy than LPA1 (EDG2) in breast carcinoma cells
Lysophosphatidic acid (LPA) acts via binding to specific G protein-coupled receptors and has been implicated in the biology of breast cancer. Here, we characterize LPA receptor exp...
Xenopus oocytes express multiple receptors for LPA-like lipid mediators
Xenopus oocytes express multiple receptors for LPA-like lipid mediators
In Xenopus laevis oocytes, both lysophosphatidic acid (LPA) and a cyclic phosphate-containing analogue 1-acyl-sn-glycero-2,3-cyclic phosphate (cLPA) isolated from Physarum polyceph...
Association of ALOX5AP gene SG13S114T/A polymorphism with acute coronary syndrome
Association of ALOX5AP gene SG13S114T/A polymorphism with acute coronary syndrome
Objective
To investigate the distribution of ALOX5AP gene SG13S114T/A polymorphism and the association of the ALOX5AP gene SG13S114T/A polymorphism with acute cor...
External validation of the Global Registry of Acute Coronary Events (GRACE) risk score: insights from the FORCE-ACS registry
External validation of the Global Registry of Acute Coronary Events (GRACE) risk score: insights from the FORCE-ACS registry
Abstract
Background
Acute coronary syndrome (ACS) patients are a heterogeneous group with a varying risk of in-hospital and long...

